Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges

Abstract Results from numerous pre-clinical studies suggest that a well known anticonvulsant drug valproic acid (VPA) and other short-chain fatty acids (SCFAs) cause significant inhibition of cancer cell proliferation by modulating multiple signaling pathways. First of all, they act as histone deacetylase (HDAC) inhibitors (HDIs), being involved in the epigenetic regulation of gene expression. Afterward, VPA is shown to induce apoptosis and cell differentiation, as well as regulate Notch signaling. Moreover, it up-regulates the expression of certain G protein-coupled receptors (GPCRs), which are involved in various signaling pathways associated with cancer. As a consequence, some pre-clinical and clinical trials were carried out to estimate anticancer effectiveness of VPA, in monotherapy and in new drug combinations, while other SCFAs were tested in pre-clinical studies. The present manuscript summarizes the most important information from the literature about their potent anticancer activities to show some future perspectives related to epigenetic therapy.

[1]  Azar Mostoufi,et al.  Synthesis, cytotoxicity, apoptosis and molecular docking studies of novel phenylbutyrate derivatives as potential anticancer agents , 2019, Comput. Biol. Chem..

[2]  K. Alzoubi,et al.  The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells , 2018, Clinical pharmacology : advances and applications.

[3]  J. Asadi,et al.  Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in breast cancer cell line , 2018 .

[4]  A. Nudelman,et al.  Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors , 2018, Journal of cellular biochemistry.

[5]  M. Veldhoen,et al.  Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases , 2018, Nature Communications.

[6]  L. Morrison,et al.  Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid. , 2017, Journal of inorganic biochemistry.

[7]  A. Afzal,et al.  Short-Chain Fatty Acids Are Antineoplastic Agents , 2017 .

[8]  G. Tsourouflis,et al.  Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. , 2017, Anticancer research.

[9]  G. Drummen,et al.  International Journal of Molecular Sciences G Protein-coupled Receptors in Cancer , 2022 .

[10]  T. Preston,et al.  Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism , 2016, Gut microbes.

[11]  T. Tomson,et al.  Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug , 2016, The Lancet Neurology.

[12]  R. Franco,et al.  Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression , 2015, Oncotarget.

[13]  Shiying Yu,et al.  Notch signaling: an emerging therapeutic target for cancer treatment. , 2015, Cancer letters.

[14]  Christopher Southan,et al.  The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors , 2015, British journal of pharmacology.

[15]  D. Coy,et al.  The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling , 2015, Journal of Cancer.

[16]  Goberdhan P Dimri,et al.  MicroRNA-31 Is a Transcriptional Target of Histone Deacetylase Inhibitors and a Regulator of Cellular Senescence* , 2015, The Journal of Biological Chemistry.

[17]  Madhusoodanan Mottamal,et al.  Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents , 2015, Molecules.

[18]  J. Issa,et al.  Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia , 2015, Cancer.

[19]  Yan-tao Han,et al.  Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy , 2015, Medicinal research reviews.

[20]  Guoyu Pan,et al.  HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review) , 2014, Oncology letters.

[21]  S. Brodie,et al.  Could valproic acid be an effective anticancer agent? The evidence so far , 2014, Expert review of anticancer therapy.

[22]  T. Utsunomiya,et al.  Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II. , 2014, Anticancer research.

[23]  D. Coy,et al.  Anti-Convulsant Drug Valproic Acid in Cancers and in Combination Anti- Cancer Therapeutics , 2014 .

[24]  Y. Morine,et al.  Effects of valproic acid as a histone deacetylase inhibitor in combination with S-1 on advanced pancreatobiliary tract cancers: Clinical study phases I and II. , 2014 .

[25]  Monica Sharma,et al.  Histone deacetylase inhibitors: pharmacotherapeutic implications as epigenetic modifier , 2014 .

[26]  Bei Liu,et al.  Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo , 2013, Oncology letters.

[27]  M. Dmoszyńska-Graniczka,et al.  [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications]. , 2013, Postepy higieny i medycyny doswiadczalnej.

[28]  Ø. Bruserud,et al.  Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents , 2013, Clinical Epigenetics.

[29]  S. Artavanis-Tsakonas,et al.  Notch signaling at a glance , 2013, Journal of Cell Science.

[30]  L. Opitz,et al.  Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. , 2013, Carcinogenesis.

[31]  J. Fuselier,et al.  Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II , 2013, Archives of Gynecology and Obstetrics.

[32]  D. Faller,et al.  Butyrate Histone Deacetylase Inhibitors , 2012, BioResearch open access.

[33]  G. Howarth,et al.  Short-Chain Fatty Acids Induce Apoptosis in Colon Cancer Cells Associated with Changes to Intracellular Redox State and Glucose Metabolism , 2012, Chemotherapy.

[34]  J. Fuselier,et al.  Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. , 2012, The oncologist.

[35]  M. Grever,et al.  Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer , 2012, Cancer Chemotherapy and Pharmacology.

[36]  M. Kobayakawa,et al.  Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies , 2011, OncoTargets and therapy.

[37]  S. Minucci,et al.  Histone deacetylases and epigenetic therapies of hematological malignancies. , 2010, Pharmacological research.

[38]  A. Dueñas-González,et al.  Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. , 2008, Cancer treatment reviews.

[39]  E. Werstiuk,et al.  Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. , 2007, European journal of pharmacology.

[40]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[41]  G. de Murcia,et al.  The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.